DYNAMICS OF DRUG RESISTANCE IN M. TUBERCULOSIS DURING THE NEW CORONAVIRUS INFECTION PANDEMIC IN DUSHANBE: THE NEED FOR URGENT MEASURES

Author:

TILLOEVA Z.KH.,

Abstract

Objective: To study the frequency and structure of primary and secondary drug resistance in M. tuberculosis (MTB) and risk factors for primary multidrug/rifampicin resistance (MDR/RR) in MTB before (Group I: 2018-2019) and during the COVID-19 pandemic (Group II: 2019-2020) in Dushanbe in patients with pulmonary tuberculosis (PTB). Methods: A cohort retrospective study included all patients with PTB tested for susceptibility to anti-tuberculosis drugs (ATD). Odds ratio (OR), 95% confidence interval (95% CI), and p-value were used to determine the significance of the association between frequency and drug susceptibility spectrum (DSS) in groups I and II; risk ratio (RR) was applied to assess a possible association between exposure and outcome. Results: The study included 559 newly diagnosed and 87 previously treated patients. Primary MDR/RR MTB was found in 21.1%, secondary – in 39.8% of patients: in group I, patients with primary MDR/RR MTB constituted 22.4%, secondary – 34.7%; in group II, the prevalence of secondary MDR/RR MTB was found to be three times higher than that of the primary resistance (OR=2.97; 95% CI=1.67-5.27, p<0.001) due to a decrease in the prevalence of primary MDR/RR MTB (19.5%) and an increase in the secondary MDR/RR MTB (47.4%). There was a statistically significant increase in the frequency of primary drug resistance to fluoroquinolones in group II compared with group I: OR=2.58 for levofloxacin (p=0.003) and OR=2.31 for moxifloxacin (p=0.027). An increase in primary MDR/RR MTB was found among healthcare workers in group II (RR=3.21; 95% CI=1.50-6.89; p=0.05), which was statistically significant in patients with diabetes mellitus in both groups: group I (RR=1.83; p=0.035) and group II (OR=2.68; p<0.001). Conclusion: The current high prevalence of primary and secondary MDR, the increase in monoresistance during the COVID-19 pandemic, and the association of MDR with employment in healthcare institutions raise concerns regarding the quality of implementation of tuberculosis (TB) infection control measures in Dushanbe. The increased frequency of resistance to fluoroquinolones requires immediate action to control their prescription. It is recommended to improve anti-TB standards among patients with diabetes mellitus. Keywords: Drug resistance, M. tuberculosis, risk factors for multidrug resistance, COVID-19.

Publisher

Avicenna Tajik State Medical University

Subject

Psychiatry and Mental health

Reference18 articles.

1. 1. Jeremiah C, Petersen E, Nantanda R, Mungai BN, Migliori GB, Amanullah F, et al. The WHO Global Tuberculosis 2021 Report - not so good news and turning the tide back to End TB. Int J Infect Dis. 2022; S1201-9712(22)00149-7.

2. 2. Tiberi S, Utjesanovic N, Galvin J, Centis R, van den Boom M, Zumla A, et al. Drug resistant TB - latest developments in epidemiology, diagnostics and management. Int J Infect Dis. 2022; S1201-9712(22)00165-5. Available from: https:// doi.org/10.1016/j.ijid.2022.03.026

3. 3. Mozhokina GN, Samoylova AG, Vasilyeva IA. Perspektivy rasshireniya medikamentoznoy terapii tuberkulyoza s mnozhestvennoy i shirokoy lekarstvennoy ustoychivost'yu [Prospects for expanding drug therapy for multiple drug resistant and extensively drug resistant tuberculosis]. Tuberkulyoz i bolezni lyogkikh. 2022;100(3):53-60. Available from: https://doi.org/10.21292/2075-1230- 2022-100-3-53-60

4. 4. Edwards BD, Edwards J, Cooper R, Kunimoto D, Somayaji R, Fisher D. Rifampin- resistant/multidrug-resistant tuberculosis in Alberta, Canada: Epidemiology and treatment outcomes in a low-incidence setting. PLoS One. 2021;16(2):e0246993.

5. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan;Makhmudova;Int J Tuberc Lung Dis,2019

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3